does retatrutide lower blood sugar From Obesity to Metabolic Health:

Provider visits, when a patient wants or needs one, add $28$35 each on top of medication cost

The primary objective was to determine whether dapagliflozin 10 mg reduces the incidence of the composite endpoint of 50% sustained decline in eGFR, progression to end-stage kidney disease (ESKD) (defined as sustained eGFR 40% and evidence of structural heart disease to determine whether dapagliflozin reduces the risk of cardiovascular death, hospitalization for heart failure or urgent heart failure visits

Arch Med Sci 19(5):15081519

Cholecystokinin decreases food intake in rats

A drug that powerfully alters GLP-1, GIP, and glucagon signaling could have effects on development that we simply do not understand yet